Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual agonists (Tirzepatide) provide superior weight loss and metabolic benefits compared to older agents like Orlistat or Phentermine, with Semaglutide and Tirzepatide showing the highest efficacy.
Newer injectable medications like Semaglutide and Tirzepatide are significantly more effective for weight loss than older oral drugs like Orlistat. Tirzepatide, in particular, has shown high efficacy in trials, with many users losing 15-20% of their body weight. These are weekly injections and are generally well-tolerated, though gastrointestinal side effects are common during dose escalation.
The newest agents, and those in clinical development, are associated with considerably greater mean efficacy than older agents... Results from a phase 3 clinical trial for obesity... showed that tirzepatide 5 mg, 10 mg and 15 mg resulted in mean placebo- subtracted weight loss over 72 weeks of 11.9%, 16.4% and 17.8% respectively
Why this rating
Based on phase 3 trials and regulatory approvals.
Source
Current and emerging medications for the management of obesity in adults
Rosalind Walmsley et al. · The Medical Journal of Australia · 2023
DOI 10.5694/mja2.51871
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →